36 results about "Transplanted kidney" patented technology

The invention relates to an early diagnosis kit and an early warning kit, in particular to an early diagnosis and early warning kit for transplanted kidney rejection reaction and a use method of the kit, and further to some proteins applied in the early warning of transplanted kidney acute rejection reaction or transplanted kidney rejection reaction. By applying a liquid protein chip (luminex) detection technique, the expression level of 96 cytokines/chemokines and receptors thereof in 266 serum samples from 142 patients having acute transplanted kidney rejection reaction and transplant recipients with stable function of transplanted kidneys are monitored and comprehensively analyzed. An early warning system for the transplanted kidney rejection reaction comprising at least one combined marker and an early diagnosis system for the transplanted kidney rejection reaction comprising at least one factor combined marker are established. The prediction and accuracy rate of the acute rejection achieve 98.6%, and the internal cross validation rates are 97.1% and 97.2%, respectively.

The invention provides a non-invasive detection system for a transplanted kidney immune state, and belongs to the technical field of post-renal transplantation ultrasonic diagnosis automatics. The non-invasive detection system for the transplanted kidney immune state includes: a data management module for acquiring personal data of a patient and one or more pieces of ultrasonic detection data according to identity recognition information of the patient by means of networking; an ultrasonic connection module for accessing an ultrasonic detector and importing current ultrasonic detection data ofthe transplanted kidney; an analysis processing module for selecting a computing model according to the personal data of the patient, and acquiring an analysis result of the ultrasonic detection data; and a result output module for formatting the analysis result and outputting the result according to the transplanting time of the patient and the analysis processing result. Accordingly, the non-invasive detection system can collect and acquire patient clinical data and ultrasonic detection data, perform automatic/semi-automatic module combination, perform automatic classification operation, and output the image-text integrated result, can lower the working load of doctors, and can facilitate result understanding.

The invention discloses a photoacoustic ultrasonic bimodal imaging system and method for transplanted kidney. The system comprises a pulse laser which is used for the transplanted kidney to generate an photoacoustic signal; the ultrasonic transducer is used for receiving the photoacoustic signal and converting the photoacoustic signal into an electric signal; the ultrasonic transceiving module isused for transmitting and receiving electric signals; a photoacoustic signal processing unit; a data collection unit; and the computer is used for controlling the pulse laser and the ultrasonic transceiving module, performing image reconstruction on the digitized photoacoustic signal to obtain a photoacoustic image, and performing color coding on the photoacoustic image to realize development of functional information such as transplanted kidney microvascular distribution, intravascular blood oxygen content, oxygenated/deoxygenated hemoglobin content and the like. Structural imaging of the transplanted kidney can be achieved, functional information such as castruty distribution, intravascular blood oxygen content and oxygenated/deoxygenated hemoglobin content of the transplanted kidney canbe provided, and namely simultaneous real-time imaging of the structure and the function of the transplanted kidney is achieved.

The invention discloses a metabolic composition for pre-operative early warning of kidney delayed graft function of a donor donated after cardiac death. The metabolic composition is prepared from oneor more selected from seven metabolites including ascorbic acid, diaminopimelic acid, cinnamic acid, isobutyl-isobutyrate, androstenedione, 3-oxocaprylic acid and uroporphyrin. The invention further discloses a screening method of the metabolic composition. In the screened metabolic composition, the binding indication rate of ascorbic acid and diaminopimelic acid is 0.823, and the binding indication rate of cinnamic acid, isobutyl-isobutyrate, androstenedione, 3-oxocaprylic acid and uroporphyrin is 0.98.

The invention discloses an ice-temperature storage method of transplanted kidney and organs. The method specifically comprises the following steps of: carrying out ether anesthesia in trachea; taking the upper abdomen median incision, cutting left or right kidney as the donor kidney; intubating into the renal artery immediately after cutting the donor kidney; filling 0-1 DEG C of organ protective liquor by virtue of pushing force of an injection pump, wherein the filling flow rate is 2.7 ml/s-2.8ml/s, and the average cooling velocity is 6.00 DEG C/minute-6.33 DEG C/minute; and stopping the filling when the temperature of the filled protective liquid flowing out of the renal veins is 1.5 DEG C-2.5 DEG C; placing the kidney in a sterilized film bag with 300ml of organ protective liquid for sealing after filling, and storing the kidney in a constant-temperature box of 0 +/-0.15 DEG C. The ice-temperature technology is adopted, so that the organ tissue is lowered in phase-transition temperature and not frozen, so that the delay storage of the transplanted organ is realized; and the ice-point limit temperature is adopted for realizing the delay storage of the transplanted organ and to recover the good function of the transplanted organ.

The invention relates to the technical field of medical instruments, in particular to a continuous refrigeration system for kidney transplantation operation. The continuous refrigeration system comprises a kidney bag, a kidney bag opening, a kidney portal opening, an in-vitro ring, an in-vivo ring, a pull wire, an inner pull ring and an outer pull ring, the kidney bag opening is formed in the upper end of the kidney bag, a transplanted kidney and smoothie mixture enters the kidney bag through the kidney bag opening, the kidney portal opening is formed in the lower end of the kidney bag, the in-vitro ring is annularly arranged at the kidney bag opening and enables the kidney bag opening to be supported and expanded, the in-vivo ring is arranged on the kidney bag in an annular mode and arranged in the body of a patient of the transplanted kidney, the outer surface of the kidney bag is connected with the pull wire, the two ends of the pull wire protrude out of the kidney bag, the lower end of the pull wire is connected with the inner pull ring, and the upper end of the pull wire is connected with the outer pull ring. The kidney bag is pulled into the in-vivo kidney anastomosis position through the inner pull ring, the kidney bag is pulled out through the outer pull ring after an operation, and the problem that a kidney supply low-temperature protection bag is inconvenient to placein a human body and take out after the operation is solved.

The invention discloses a marker for predicting the range and depth of kidney infection of polyoma virus and application thereof. Experiments verify that the combined detection of 58K Golgi protein and polyoma virus specific antigen has important application value in predicting the range and depth of transplanted kidney infection and prognosis of kidney transplantation patients, and is helpful forrisk stratification of infection and adoption of appropriate treatment strategies. The sample adopted by the detection strategy of the invention is urine sediment cells, which can be realized by non-invasive means, and the operation is simple, and most of the processes can be automated and almost can be carried out in each transplantation center.

The invention provides an application of a recombinant human myeloid-derived growth factor in preparation of a medicine for treating renal ischemia reperfusion injury. The recombinant human medullary-derived growth factor can reduce serum creatinine and urea nitrogen levels of mice suffering from renal ischemia reperfusion injury, improves renal functions after renal ischemia reperfusion injury, has a kidney protection effect and can relieve oxidative stress injury caused by renal ischemia reperfusion injury. The traditional Chinese medicine composition brings hopes for improving the life quality of kidney transplantation patients and prolonging the survival time of transplanted kidneys, and also has a certain far-reaching influence on prevention and treatment of ischemia reperfusion injuries of other tissues and organs.

The invention discloses a postoperative monitoring device for a kidney transplantation recipient, and the device comprises: a data collection unit which is used for collecting peripheral blood transcriptome data of the kidney transplantation recipient; a database unit which is used for storing the peripheral blood transcriptome data; and a support vector machine unit which is used for generating a monitoring report based on the peripheral blood transcriptome data. Study data pre-stored in a database unit are called through the support vector machine unit, a classifier model is constructed and tested, and the classifier model predicts the probability of occurrence of postoperative acute rejection of a kidney transplantation recipient based on peripheral blood transcriptome data of the kidney transplantation recipient and generates a detection report. The kidney function condition of a kidney transplantation recipient is accurately monitored while non-invasive detection is achieved, and meanwhile a detection report can provide a theoretical necessary basis for further confirmation and diagnosis of transplantation kidney needle biopsy.

The invention discloses a metabolic composition for pre-operative early warning of transplanted kidney delayed rework of a donation receptor after cardiac death. The metabolic composition is composedof one or more than one of four metabolites including glucuronic acid, ganglioside, physalis angulata sterol and thiophenol. The invention further discloses a screening method of the pre-operative early warning of transplanted kidney delayed rework of donation receptor after cardiac death. In the screened metabolic composition, the combination indication rate of glucuronic acid and ganglioside is0.885, and the combination indication rate of physalis angulata sterol and thiophenol is 0.953.

The invention discloses a metabolic composition for early detection of transplanted kidney acute rejection. The metabolic composition is composed of one or more of 10 metabolite combinations of aminopterin, cane sugar, estrone, galactoinositol, cortisone, quinolone sugar, lactose, lyxose, palmitic acid and catechol. The invention further discloses a screening method of the metabolic composition. In the screened metabolite composition, the levels of aminopterin, cane sugar, estrone, galactoinositol, cortisone, quinolone sugar, lactose and lysose are increased, and the levels of palmitic acid and catechol are reduced, so that the metabolite composition has guiding significance for diagnosis of acute rejection; in the metabolite composition, the independent indication rate of the metabolite is 0.609-0.762, and the binding indication rate reaches 0.792; and in the metabolite composition, the core components are sucrose, galactoinositol, lactose, lyxose and quinolone sugar which jointly participate in a galactose metabolic pathway.

Provided is a method for evaluating the likelihood of the onset or progression of transplanted kidney chronic rejection or chronic kidney disease in a subject, wherein the amount of SYT17 protein in a urine-derived sample collected from the subject is used as an index. Furthermore, the present invention provides a pharmaceutical composition for preventing and/or treating chronic rejection of transplanted kidney or chronic kidney disease, comprising at least one substance selected from the group consisting of a specific antibody against SYT17, a derivative thereof, and an inhibitory nucleic acid against SYT17, and also comprising at least one substance selected from the group consisting of a specific antibody against SYT17, a derivative thereof, and an inhibitory nucleic acid against SYT17. Provided is a test kit for evaluating the likelihood of the onset or progression of transplanted kidney chronic rejection or chronic kidney disease, the test kit comprising an antibody specific to SYT17 or a derivative thereof.

The invention proposes a novel method of treatment of patients with chronic kidney disease (CKD). The method includes two stage transplantations of a patient's kidney: first, one of kidneys of the patient with CKD is transplanted into a young healthy animal recipient (preferably a pig), whereas a kidney of a living person or cadaver or an animal recipient is temporarily transplanted into the body of the patient. Homeostatic factors of the animal recipient will cause the transplanted kidney recovery. In the second stage, the recovered kidney is autotransplantated back to the patient. Up to this time both the animal recipient and the patient are treated by immunosuppressive drugs.

If an allogenic kidney is transplanted into the patient's body, the patient's kidney is transplanted into the body of a young healthy pig and after it's recovery the patient's kidney re-transplanted instead of the allogenic kidney.